Summit Therapeutics Q2 Adjusted Loss Widens-February 2024-www.financetom.com

Summit Therapeutics Q2 Adjusted Loss Widens

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Summit Therapeutics Q2 Adjusted Loss Widens

Aug 11, 2025 2:50 PM

05:28 PM EDT, 08/11/2025 (MT Newswires) -- Summit Therapeutics ( SMMT ) reported Q2 adjusted net loss late Monday of $0.12 per diluted share, widening from $0.07 a year earlier.

The company did not report any revenue for the quarter.

Previous page： GlobalFoundries finance chief John Hollister departs, Sam Franklin named interim CFO Next page： GlobalFoundries finance chief John Hollister departs, Sam Franklin named interim CFO

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

GlobalFoundries finance chief John Hollister departs, Sam Franklin named interim CFO

Oct 27, 2025

Oct 27 (Reuters) - GlobalFoundries' ( GFS ) John Hollister has stepped down from the CFO position and will be succeeded by Sam Franklin on an interim basis, the contract chipmaker said on Monday. The management reshuffle comes at a time when the company has pledged to invest $16 billion partly towards building more manufacturing facilities on American soil amid...

GlobalFoundries finance chief John Hollister departs, Sam Franklin named interim CFO

Oct 27, 2025

(Reuters) -GlobalFoundries' ( GFS ) John Hollister has stepped down from the CFO position and will be succeeded by Sam Franklin on an interim basis, the contract chipmaker said on Monday. The management reshuffle comes at a time when the company has pledged to invest $16 billion partly towards building more manufacturing facilities on American soil amid U.S. President Donald...

Stock exchange operator TMX's Q3 revenue beats estimates on strong derivatives trading

Oct 27, 2025

Overview * TMX Group ( TMXXF ) Q3 revenue rises 18% yr/yr, beating analyst expectations * Adjusted EPS for Q3 beats consensus, reflecting strong operational performance * TMX Group ( TMXXF ) completes acquisition of Verity Outlook * TMX Group ( TMXXF ) focuses on accelerating growth and delivering shareholder value in 2025 * Company highlights strategic focus on global...

Australia's CSL delays vaccine division spin-off amid US market volatility

Oct 27, 2025

Oct 28 (Reuters) - Australian biotech CSL said on Tuesday it was no longer targeting to complete the spin-off of its vaccine division in fiscal 2026, citing heightened volatility in the U.S. influenza vaccine market. ...